While previous studies have demonstrated that synaptotagmin plays an essential role in evoked neurotransmitter release, it has been difficult to determine whether it acts to facilitate or inhibit release. To address this question, we used acute genetic manipulations to alter the expression-of synaptotagmin in Aplysia neurons. Transient overexpression of synaptotagmin in acutely dissected cholinergic neurons and in cultured glutaminergic neurons decreased the amplitude of the excitatory postsynaptic potential (EPSP) by 32% and 26%, respectively. In contrast, treatment of cultured presynaptic neurons with synaptotagmin antisense oligonucleotides increased the amplitude of the EPSP by 50-75%. These results are consistent with a role of synaptotagmin as an inhibitor of release.
Neurotransmitter release is distinguished from other forms of exocytosis by its tight spatial and temporal regulation. Since calcium influx is the signal for release, there must be one or more calcium-sensing proteins present at the active zone, acting either to facilitate fusion in the presence of calcium or to inhibit fusion in its absence. Synaptotagmin has many of the characteristics expected of such a calcium sensor. It contains two sequences homologous tothe C2 domain of protein kinase C and has been found to bind calcium in a phospholipiddependent manner in vitro (1) (2) (3) . Synaptotagmin coprecipitates with calcium channels (4) and with several plasma membrane proteins, including syntaxin (5) and the neurexins (6) . Synaptotagmin is also a receptor for clathrin AP-2, suggesting that it may also be involved in the endocytosis of synaptic vesicles (3, 7) .
Several previous studies have addressed the function of synaptotagmin in neurotransmitter release. Synthetic C2 domain peptides and antibodies against synaptotagmin inhibit release when microinjected into individual cells (8, 9) . Caenorhabditis elegans, Drosophila, and mice bearing mutations in synaptotagmin all had impaired synaptic function (10) (11) (12) (13) . Biochemical studies of the interaction of synaptotagmin with other synaptic membrane proteins suggest that it functions prior to the final fusion step (14, 15) . The results of these studies have led to three alternative views of the function of synaptotagmin: it docks vesicles at the plasma membrane, it promotes vesicle fusion, or it inhibits vesicle fusion.
We have designed experiments using acute genetic manipulations to increase or decrease synaptotagmin expression in Aplysia californica neurons. First, we cloned the Aplysia homolog of synaptotagmin and then overexpressed it in cholinergic neurons of acutely dissected Aplysia ganglia and in glutaminergic sensory neurons cocultured with a single motor neuron. Second, we used antisense oligonucleotides to reduce the expression of endogenous synaptotagmin in Aplysia sensory-motor neuron cocultures. In both cases, we measured the effect of our manipulations on synaptic strength. Our results are consistent with synaptotagmin acting as an inhibitor of neurotransmitter release. § MATERIALS AND METHODS Cloning. The coding region of synaptotagmin A from the marine ray Discopyge ommata was amplified by PCR (PerkinElmer/Cetus) and used to screen an Aplysia nervous system cDNA library cloned in the A-ZAP vector (Stratagene) as described (16) .
Antibodies. Antibodies were generated by Berkeley Antibody (Richmond, CA) against a maltose binding proteinsynaptotagmin fusion protein (New England Biolabs) containing residues 1-67 fused to residues 93-426 of synaptotagmin. The antiserum was purified using a fusion protein affinity column (Pierce).
Overexpression. The entire coding region ofAplysia synaptotagmin was amplified from the cDNA by PCR (PerkinElmer/Cetus) and ligated into the pNEX6 expression vector (17) to create pNEX8-p65. Two complementary synthetic oligonucleotides encoding the influenza hemagglutinin (HA) epitope YPYDVPDYA were ligated into Sal I-digested pNEX8-p65 to insert the tag between Arg-411 and Pro-412 of Aplysia synaptotagmin. Generation of pNEX&-lacZ has been described (18) .
DNA was prepared for microinjection as described (17) and injected by brief pressure pulses applied to microelectrodes beveled to a resistance of 20 Mfl. In cultured Aplysia neurons, overexpression of synaptotagmin was verified by indirect immunofluorescence using affinity-purified anti-synaptotagmin antibodies and expression of lacZ was verified by enzymatic staining for ,B-galactosidase as described (17) . Immunofluo *To whom reprint requests should be sent at the present address:
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(end-capped) were found to be effective at a dose of 30 ,uM without being toxic. For bath application of antisense oligonucleotides, a lOX solution of oligonucleotides suspended in L15 medium (Sigma) was added to the culture medium immediately prior to plating of the sensory neuron and was replenished daily. In other experiments, oligonucleotides were injected into sensory cells 3-12 hr after plating by pressure application to microelectrodes containing 300 ,uM oligonucleotides in 0.5 M potassium acetate/10 mM Tris, pH 7.2. The final intracellular concentration of oligonucleotides was estimated to be 10-30 ,uM.
Immunocytochemistry and Immunoblotting. CulturedAplysia neurons were prepared for immunohistochemistry as described (19) . Antibody specificity was determined by immunoblotting as described (19) . In competition experiments, affinity-purified anti-synaptotagmin antibodies were preincubated with a 10-fold molar excess of maltose binding proteinsynaptotagmin fusion protein. Immunoblots of pedal ganglia neurons microinjected with pNEX8-p65 HA were incubated with mouse monoclonal anti-HA antibody 12CA5 (Berkeley Antibody, Richmond, CA) diluted 1:2500 followed by horseradish peroxidase-conjugated goat anti-mouse antibody (Pierce) diluted 1:5000. Immunoblots were stripped according to the manufacturer's instructions (Amersham).
Aplysia Culture, Dissection, and Electrophysiology. Sensory cells (one or two) isolated from the pleural ganglia of adult (80-100 g) animals were plated with L7 motor cells from the abdominal ganglia of juvenile (1.5-4 g) animals as described (20, 21) . In overexpression studies, electrophysiological recordings were as described (21, 22) . In some antisense experiments, the sensory neuron was also impaled with a microelectrode to record the action potential triggered by a brief injection of depolarizing current (5-10 msec, 2-6 nA).
The buccal ganglia were dissected from 70-to 100-g animals and desheathed, and either cell B4 or B5 was randomly chosen to be injected with plasmid. Synaptic potentials were recorded as described in Kaang et al. (17) and Gardner and Kandel (23) . Because of an upward drift in the excitatory postsynaptic potential (EPSP) amplitude with time, the effect of overexpression was normalized by the change in the uninjected presynaptic cell: % change = [(D2 x C1)/(D1 x C2) -1] x 100, where Dl = the initial EPSP amplitude of the injected cell, D2 = the final EPSP amplitude of the injected cell, Cl = the initial EPSP amplitude of the uninjected cell, and C2 = the final EPSP amplitude of the uninjected cell.
The statistical significance of antisense treatment in sensory-motor cocultures and of overexpression in the buccal ganglia was tested using an unpaired Student's t test. The statistical significance of overexpression in sensory-motor cocultures was tested using a one-way analysis of variance followed by a Newman-Keuls range of means test. All results are given as means ± standard error.
RESULTS
Cloning of the Aplysia Synaptotagmin Homolog and Identification of the Endogenous Gene Product. We isolated Aplysia synaptotagmin cDNA clones using low stringency hybridization to a marine ray (D. ommata) synaptotagmin A-specific probe (24) . TheAplysia synaptotagmin open reading frame encodes a polypeptide of 426 residues with a calculated molecular mass of 47,455 Da (Fig. 1) . Aplysia synaptotagmin shares the putative domain structure of all other synaptotagmin isoforms: two cytoplasmic repeats of the C2 domain, a single transmembrane spanning region, and an intravesicular amino terminus (3, 25) .Aplysia synaptotagmin shares sequence identity of 55.6% with synaptotagmin A from D. ommata and 56.1% with rat synaptotagmin 1.
From 300,000 clones screened with the synaptotagmin A clone from D. ommata, the five positively hybridizing clones (27) . Normalizing for this upward drift (see Materials and Methods), we found a 32% decrease in the postsynaptic response in cells that were injected with the synaptotagmin plasmid compared to those injected with control plasmid or buffer alone (P < 0.05; Fig. 3C ).
To rule out the possibility that the decreased EPSP resulted from an altered response to the acute injury of dissection, we overexpressed synaptotagmin in cultured glutaminergic sensory neurons, in which the synaptic strength of control synapses does not change significantly over a 24-hr period. EPSPs were recorded from the motor neuron in response to a series of four action potentials evoked in the sensory neuron once every 20 sec. This provided a measure of baseline synaptic strength as well as of the degree of homosynaptic depression (28, 29) .
Sensory cells were then microinjected with pNEX8-p65 or pNEX6-lacZ. Fifteen to 20 hr later, the stimulus series was repeated and the cells were processed for indirect immuno-A Buccal Ganglia 1st Recording 2nd Recording fluorescence using affinity-purified anti-synaptotagmin antibody or for enzymatic staining for ,3-galactosidase. As shown in Fig. 4 A and C, synaptotagmin and lacZ were expressed at very high concentrations and were present in the synapse at the time of fixation. Overexpression of full-length synaptotagmin in sensory cells depressed the initial EPSP by 26% [P < 0.01 vs. injected but not overexpressing cells (impaled); P < 0.05 vs. lacZ-expressing cells; Fig. 3D ]. Overexpression of synaptotagmin had no effect on the degree of homosynaptic depression (data not shown) nor did overexpression qualitatively affect the morphology of the presynaptic cell.
Antisense Oligonucleotides Enhance Neurotransmitter Release. Through the application of antisense oligonucleotides, we attempted to reduce the amount of endogenous synaptotagmin in cultured cells. When Aplysia neurons are cultured, the cell body and initial axon segment are pulled out of the ganglion, leaving the synaptic terminals behind. Antisense oligonucleotides applied immediately might therefore block synthesis of the synaptic proteins required for the new synapse formed in vitro.
We used a 17-bp antisense oligonucleotide complementary to a sequence that is conserved among the Aplysia homolog and isoforms 1 and 2 of rat synaptotagmin. We also performed a set of experiments using antisense oligonucleotides complementary to a sequence spanning the initiation codon. Oligonucleotides were either added to the culture medium or injected into the presynaptic cell.
We examined the effects of the oligonucleotides on synaptic transmission by recording from the synapse on day 4 injected into the presynaptic cell. By contrast, there was no significant difference in EPSP amplitude between cells injected with control oligonucleotides and untreated cells. We also examined the effects of synaptotagmin antisense oligonucleotides on two forms of short-term synaptic plasticity, homosynaptic depression and serotonin-mediated facilitation of the depressed synapse (dishabituation) (28, 29) , neither of which was altered (data not shown).
Using our anti-Aplysia synaptotagmin antibody, we were not able to detect any consistent effect of antisense treatment on protein levels. The apparent cross-reactivity of our antibody with other synaptotagmin isoforms or antigenically related proteins may have obscured any change in the protein concentration of the targeted isoform. However, the effect of the antisense oligonucleotides was specific: control oligonucleotides did not affect initial EPSP strength, and antisense oligonucleotides increased initial EPSP strength without affecting homosynaptic depression or heterosynaptic dishabituation.
DISCUSSION
Does Synaptotagmin Facilitate or Inhibit Release? Our studies confirm previous work showing that synaptotagmin plays an important role in synaptic transmission. From this earlier work, however, it was difficult to determine whether synaptotagmin acts to facilitate or inhibit release.
In three genetically modified animals, C. elegans, Drosophila, and mouse, loss of synaptotagmin largely abolished evoked neurotransmitter release (10) (11) (12) (13) . However, recordings from the Drosophila neuromuscular junction of third instar larvae of synaptotagmin hypomorphs revealed that while evoked release was diminished, spontaneous release was increased (10, 11, 30) . These findings are consistent with synaptotagmin acting to inhibit vesicle fusion. In its complete absence, vesicles would constantly undergo spontaneous fusion, thus depleting the pool of vesicles available for synchronous release in response to the calcium signal (31) . That synaptotagmin may inhibit release is further supported by the findings of Sollner et al. (15) , showing that synaptotagmin forms a complex with synaptobrevin, syntaxin, and SNAP-25 and is displaced from this complex by a-SNAP prior to formation of a 20S complex containing the fusion factor NSF.
In mice bearing mutations of synaptotagmin 1, however, spontaneous release was unaffected, the rapid phase of evoked release was eliminated, and there were no obvious alterations in active zone morphology (13) . In contrast to the findings in Drosophila, the findings in mice are more consistent with synaptotagmin acting to promote vesicle fusion. The discrepancy between the two mutant animals may reflect differences between vertebrates and invertebrates. More likely, however, it may reflect differences in the physiological function of the particular isoform eliminated in each mutant animal.
Synaptotagmin Acts as an Inhibitor of Neurotransmitter Release in Aplysia. We have attempted to increase and decrease synaptotagmin expression and to assess the effects of such changes on synaptic function. In the Aplysia culture system, changes in EPSP amplitude are likely to reflect changes in transmitter release because there is neither the complication of multiple synaptic inputs nor that of nervous system development. In addition, because the cells are electrically silent in the absence of extracellular stimulation, we can interpret changes in the size of the initial EPSP as changes in exocytosis as opposed to endocytosis of synaptic vesicles following release.
When we overexpressed synaptotagmin, immunostaining indicated a large increase in protein concentration throughout the cell. This resulted in a 26% decrease in EPSP amplitude in cultured cells and a 32% decrease in EPSP amplitude in dissected ganglia. There are several explanations for why such a large increase in protein expression should result in a relatively small change in release. (i) Synaptotagmin may act with one or more cofactors that are present at limited concentrations. (ii) Newly expressed synaptotagmin may not be efficiently incorporated into vesicles residing at the active zone. (iii) The small size of the vesicles may permit only a limited number of proteins to be present on their surface and this maximum may normally be reached. If any of these explanations apply, one would predict that decreasing the concentration of synaptotagmin would produce a much greater effect.
Indeed, when we used antisense oligonucleotides to block synaptotagmin synthesis during synapse formation, we saw a 50-75% increase in EPSP amplitude. This occurred despite the fact that we were unable to determine whether antisense treatment reduced synaptotagmin concentration since our antibody appeared to cross-react with other synaptotagmin isoforms or proteins with common epitopes. It 
